Skip to content

Hormonal, bone mass and lean muscle evaluation in patients after high-dose chemotherapy for autologous hematopoietic stem cell transplantation for Lymphoma

Hormonal evaluation, bone mass and Sarcopenia in patients after high-dose chemotherapy for autologous hematopoietic stem cell transplantation for Lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-4xtk65g
Enrollment
Unknown
Registered
2023-10-09
Start date
2022-05-06
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormones

Interventions

This is a cross-sectional cohort study with patients transplanted for lymphoma since 2004 at the HU-UFJF, with the range of age between 18 and 70. These patients were contacted through telephone call,
V03.175.500

Sponsors

Christianne Leal
Lead Sponsor
Universidade Federal de Juiz de Fora
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients volunteers between 18 and 70 years old who underwent autologous hematopoietic stem cell transplantation for lymphoma and wanted to participate in the research by signing the informed consent form

Exclusion criteria

Exclusion criteria: Age 70 years old and people that do not want to be included

Design outcomes

Primary

MeasureTime frame
Evaluate hormonal changes mainly in the hypothalamic pituitary gonad axis, which is known to be the most compromised, in addition to bone mass and sarcopenia, since these patients underwent different chemotherapy protocols in addition to very high-dose pre-transplant chemotherapy. As data are being collected from patients who underwent transplantation a long time ago (since 2004) and recently , the aim is to identify acute and chronic toxicities for better pre-transplant counseling and post-transplant follow-up.

Secondary

MeasureTime frame
it is spected to see some associations of comorbidities of each patient with clinical outcomes like metabolic and hormonal changes in addition loss of bone mass and sarcopenia

Countries

Brazil

Contacts

Public ContactChristianne Leal

Universidade Federal de Juiz de Fora

christianneleal74@gmail.com+5532988285484

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 5, 2026